MASLD or MAFLD: fatty liver by any name will pose the same challenge

References

[1] Lonardo A,Alswat KA.History of nonalcoholic fatty liver disease.Int J Mol Sci2020;21:5888 PMCID:PMC7460697

[2] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.Mayo Clin Proc1980;55:434-8

[3] Schaffner F.Nonalcoholic fatty liver disease.Prog Liver Dis1986;8:283-98

[4] Younossi ZM,Paik JM,Van Dongen C.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[5] Battistella S,Grasso M.Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management.Clin Mol Hepatol2023;29:S286-301 PMCID:PMC10029965

[6] Daher D,Singal AG.Non-alcoholic fatty liver disease-related hepatocellular carcinoma.J Liver Cancer2023;23:127-42 PMCID:PMC10202236

[7] Grander C,Tilg H.Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options.Cardiovasc Res2023;119:1787-98 PMCID:PMC10405569

[8] Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.

[9] Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. PMCID:PMC10653297

[10] Lancet Gastroenterology Hepatology. Redefining non-alcoholic fatty liver disease: what’s in a name?.Lancet Gastroenterol Hepatol2020;5:419

[11] Premkumar M.Lean fatty liver disease: through thick and thin.J Clin Exp Hepatol2021;11:523-7 PMCID:PMC8414406

[12] Chen L.From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: controversy and consensus.World J Hepatol2023;15:1253-7 PMCID:PMC10784812

[13] Fouad Y.Metabolic-associated fatty liver disease: new nomenclature and approach with hot debate.World J Hepatol2023;15:123-8 PMCID:PMC10011913

[14] Duseja A,Mehta M.Patients with metabolic-dysfunction associated fatty liver disease (MAFLD) without associated etiologies and non-MAFLD non-alcoholic fatty liver disease (NAFLD) have similar liver disease severity - data from Indian Consortium on NAFLD (ICON-D).J Clin Exp Hepatol2022;12:S73-4

[15] Gofton C,Zheng MH.MAFLD: how is it different from NAFLD?.Clin Mol Hepatol2023;29:S17-31 PMCID:PMC10029949

[16] Albhaisi S,Sanyal AJ.Non-alcoholic fatty liver disease in lean individuals.JHEP Rep2019;1:329-41 PMCID:PMC7001558

[17] Singh SP,Reddy KR.Non-alcoholic fatty liver disease: not time for an obituary just yet!.J Hepatol2021;74:972-4

[18] Duseja A.Changing nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease - not only premature but also confusing.J Clin Exp Hepatol2021;11:278-9 PMCID:PMC7953006

[19] Singh SP,Butt AS.NAFLD vs MAFLD: South Asian NAFLD patients don’t favor name change.Euroasian J Hepatogastroenterol2022;12:S1-4 PMCID:PMC9681577

[20] Younossi ZM,Sanyal AJ.From NAFLD to MAFLD: implications of a premature change in terminology.Hepatology2021;73:1194-8

[21] Society for Paediatric Gastroenterology Hepatology (ESPGHAN) and European Association for the Study of the Liver (EASL), on behalf of co-authors. Electronic address: [e-mail]; European Society for Paediatric Gastroenterology Hepatology (ESPGHAN) and European Association for the Study of the Liver (EASL), on behalf of co-authors. Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease.Lancet Gastroenterol Hepatol2023;8:598-600

[22] Singh SP,Anirvan P,Mahtab MA.Nonalcoholic fatty liver disease vs metabolic-associated fatty liver disease vs metabolic dysfunction-associated steatotic liver disease: what’s in the name?.Euroasian J Hepatogastroenterol2024;14:1-4 PMCID:PMC11249896

[23] García-Compeán D, Jiménez-Rodríguez AR. NAFLD vs MAFLD. The evidence-based debate has come. Time to change? Ann Hepatol. 2022;27:100765.

[24] Anand AC.MASLD, MLA pesarattu and other developments.J Clin Exp Hepatol2025;15:102465 PMCID:PMC11663955

[25] Schuckit MA,Smith TL.Characteristics associated with denial of problem drinking among two generations of individuals with alcohol use disorders.Drug Alcohol Depend2020;217:108274 PMCID:PMC7736262

[26] Portincasa P.NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care.Intern Emerg Med2023;18:993-1006 PMCID:PMC10326150

[27] Arab JP,Rehm J.Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease.J Hepatol2025;82:744-56

[28] Israelsen M, Torp N, Johansen S, et al; GALAXY consortium. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024;9:218-28.